Trademark: 87806064
Word
ULTRAGENYX GENE THERAPY
Status Date
Monday, May 16, 2022
Filing Date
Wednesday, February 21, 2018
Published for Opposition
Tuesday, February 12, 2019
Abandoned Date
Monday, May 16, 2022
5 Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, and hematologic diseases and disorders
1 Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, all for in-vivo laboratory use in gene therapy
44 Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders
42 Biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays
The mark consists of the word "ultragenyx" in lower case letters above the words "gene therapy". The formative "ultra" and the words "gene therapy" are purple and the formative "genyx" is green. The letter "x" in "genyx" is stylized and features an enlongated stroke reaching above and below the word "ultragenyx". A gray hexagon is below the formative "ultra" and to the left of the words "gene therapy." A double helix, one strand of which is purple and one strand of which is green, is vertically oriented inside the gray hexagon.
The color(s) purple, green and gray is/are claimed as a feature of the mark.
"GENE THERAPY"
May 16, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
May 16, 2022
Abandonment - No Use Statement Filed
Oct 28, 2021
Notice Of Approval Of Extension Request E-Mailed
Oct 27, 2021
Sou Extension 5 Granted
Oct 4, 2021
Sou Extension 5 Filed
Oct 6, 2021
Case Assigned To Intent To Use Paralegal
Oct 4, 2021
Teas Extension Received
Mar 27, 2021
Notice Of Approval Of Extension Request E-Mailed
Mar 25, 2021
Sou Extension 4 Granted
Mar 25, 2021
Sou Extension 4 Filed
Mar 25, 2021
Teas Extension Received
Sep 30, 2020
Notice Of Approval Of Extension Request E-Mailed
Sep 28, 2020
Sou Extension 3 Granted
Sep 28, 2020
Sou Extension 3 Filed
Sep 28, 2020
Teas Extension Received
Mar 31, 2020
Notice Of Approval Of Extension Request E-Mailed
Mar 27, 2020
Sou Extension 2 Granted
Mar 27, 2020
Sou Extension 2 Filed
Mar 27, 2020
Teas Extension Received
Oct 3, 2019
Notice Of Approval Of Extension Request E-Mailed
Oct 1, 2019
Sou Extension 1 Granted
Oct 1, 2019
Sou Extension 1 Filed
Oct 1, 2019
Teas Extension Received
Apr 9, 2019
Noa E-Mailed - Sou Required From Applicant
Feb 12, 2019
Official Gazette Publication Confirmation E-Mailed
Feb 12, 2019
Published For Opposition
Jan 23, 2019
Notification Of Notice Of Publication E-Mailed
Jan 4, 2019
Approved For Pub - Principal Register
Dec 26, 2018
Examiner's Amendment Entered
Dec 26, 2018
Notification Of Examiners Amendment E-Mailed
Dec 26, 2018
Examiners Amendment E-Mailed
Dec 26, 2018
Examiners Amendment -Written
Dec 12, 2018
Teas/Email Correspondence Entered
Dec 11, 2018
Correspondence Received In Law Office
Dec 11, 2018
Teas Response To Office Action Received
Jun 12, 2018
Notification Of Non-Final Action E-Mailed
Jun 12, 2018
Non-Final Action E-Mailed
Jun 12, 2018
Non-Final Action Written
Jun 5, 2018
Assigned To Examiner
Mar 2, 2018
Notice Of Design Search Code E-Mailed
Feb 28, 2018
New Application Office Supplied Data Entered In Tram
Feb 24, 2018
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
